In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge Presented ByDr Thomas Yau, University of Hong Kong, China TrialPhase 3, CheckMate 459 ConferenceESMO 2019 26 November, 2019 20:21